Charming Medical (MCTA) appoints Matthew Mo Kan Tsui as independent director and audit chair
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Charming Medical Limited appointed Matthew Mo Kan Tsui as a non-employee, independent director effective April 2, 2026, with annual compensation of HK$384,000. He will serve until a successor is elected and qualified or an earlier departure.
The Board determined that Mr. Tsui is an independent director under U.S. SEC and Nasdaq rules and that he qualifies as an “audit committee financial expert” with required financial sophistication. He will chair the Audit Committee and sit on the Compensation and Nominating Committees. Mr. Tsui brings over 20 years of experience in accounting, corporate finance, capital markets, and audit, including roles at KPMG and listed Hong Kong companies, and holds professional CPA memberships and an accounting and finance degree.
Positive
- None.
Negative
- None.
Key Figures
Director annual compensation: HK$384,000
Director age: 44
Experience: Over 20 years
3 metrics
Director annual compensation
HK$384,000
Annual compensation for Matthew Mo Kan Tsui as director
Director age
44
Age of Matthew Mo Kan Tsui at appointment
Experience
Over 20 years
Experience in accounting, corporate finance, and capital markets
Key Terms
independent director, audit committee financial expert, Regulation S-K, Nasdaq Stock Market LLC Listing Rules, +1 more
5 terms
independent director financial
"Mr. Tsui will be serving on the Board of Directors as a non-employee, independent director."
An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.
audit committee financial expert financial
"qualifies as an “audit committee financial expert” as defined under Item 407(d)(5) of Regulation S-K"
A person on a company’s board who has deep knowledge of accounting, financial reporting and auditing, able to understand and question the books, controls and audit work like a trained mechanic inspecting an engine. Investors care because that expertise helps spot errors, weaknesses or misleading statements early, improving the likelihood that financial reports are accurate and reducing the risk of surprises that can hurt a company’s value.
Regulation S-K regulatory
"Item 407(d)(5) of Regulation S-K promulgated under the Securities Exchange Act of 1934"
A set of U.S. Securities and Exchange Commission rules that tell public companies which narrative and qualitative details must be disclosed in filings, such as risk factors, management discussion, executive pay, legal proceedings and business description. Think of it as a standardized checklist or blueprint that ensures investors get the same types of background information from every company so they can compare risks, management quality and strategy before making investment decisions.
Nasdaq Stock Market LLC Listing Rules regulatory
"financial sophistication under Rule 5605(c)(2)(A) of the Nasdaq Stock Market LLC Listing Rules."
ESG disclosures financial
"he oversees financial reporting, internal control over financial reporting, risk management, and ESG disclosures."
ESG disclosures are the public reports a company makes about its environmental practices (like pollution and resource use), social impacts (like labor standards and community relations), and governance (how it is run and overseen). Think of them as a report card that helps investors judge non-financial risks and strengths that can affect future profits, legal exposure, reputation, and access to capital, so investors use them to compare companies’ long-term sustainability and risk profile.
FAQ
What board role did Charming Medical (MCTA) give to Matthew Mo Kan Tsui?
Charming Medical appointed Matthew Mo Kan Tsui as a non-employee, independent director. He will also chair the Audit Committee and serve on the Compensation and Nominating Committees, strengthening oversight of financial reporting, governance, and executive pay with his accounting and capital markets background.
How much is Matthew Mo Kan Tsui paid as a director of Charming Medical (MCTA)?
Matthew Mo Kan Tsui will receive annual compensation of HK$384,000 as a director. This compensation reflects his responsibilities as an independent director, Audit Committee chair, and member of the Compensation and Nominating Committees, drawing on more than 20 years of finance and audit experience.
Is Matthew Mo Kan Tsui considered independent under U.S. and Nasdaq rules for MCTA?
The Board determined that Matthew Mo Kan Tsui is an “independent” director under applicable U.S. SEC and Nasdaq Marketplace Rules. This status supports stronger governance by ensuring he is free from relationships that could impair objective judgment in overseeing management and financial reporting.
What committees will Matthew Mo Kan Tsui serve on at Charming Medical (MCTA)?
Matthew Mo Kan Tsui will be chairman of the Audit Committee and a member of the Compensation Committee and Nominating Committee. These roles place him at the center of financial reporting oversight, executive compensation decisions, and board nomination processes for Charming Medical.
What qualifies Matthew Mo Kan Tsui as an audit committee financial expert for MCTA?
The Board concluded he qualifies as an “audit committee financial expert” under Item 407(d)(5) of Regulation S-K. His prior KPMG audit manager role, experience with HKFRS/IFRS financial statements, IPO work, and oversight of financial reporting and risk management at Hong Kong listed companies support that designation.
Does Matthew Mo Kan Tsui have family ties to Charming Medical (MCTA) insiders?
There are no family relationships between Matthew Mo Kan Tsui and any employees or board members of Charming Medical. This lack of family ties supports his independence and helps ensure objective judgment in his board and committee responsibilities, particularly on the Audit and Compensation Committees.